Clinical trial
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of…
NCT00034346 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00034346 |
|---|---|
| Title | ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) |
| Official title | A Two Part, Multiple Dose Clinical Trial of the Safety and Efficacy of ABX-EGF in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small Cell Lung Cancer |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Small Cell Lung Cancer, Neoplasm Metastasis, Lung Cancer |
| Intervention type | Drug |
| Interventions | ABX-EGF, paclitaxel, carboplatin |
| Enrollment | 194 |
| Start date | Jan 1, 2002 |
| First posted | Apr 26, 2002 |
| Last update posted | Dec 24, 2007 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: